Cover Image
市場調查報告書

激躁性結腸症:開發中產品分析

Irritable Bowel Syndrome - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232842
出版日期 內容資訊 英文 140 Pages
訂單完成後即時交付
價格
Back to Top
激躁性結腸症:開發中產品分析 Irritable Bowel Syndrome - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 140 Pages
簡介

激躁性結腸症(IBS)是一般最常見的大腸(結腸)疾病。主要症狀有肌肉痙攣和腹痛、氣體過多、下痢腹瀉等。主要治療方法有止瀉劑、抗膽鹼作用藥、抗憂鬱劑、抗生素治療等。

本報告提供全球各國治療激躁性結腸症(IBS)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

激躁性結腸症概要

治療藥的開發

  • 開發中產品的概要

激躁性結腸症:企業開發中的治療藥

激躁性結腸症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

激躁性結腸症:企業開發中的產品

激躁性結腸症治療藥的開發企業

  • 4D Pharma Plc
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Alfa Wassermann S.p.A
  • Allergan Plc
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • CJ HealthCare Corp.
  • Enterome Bioscience SA
  • Innovate Biopharmaceuticals, Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Lexicon Pharmaceuticals, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Protagonist Therapeutics Inc.
  • RaQualia Pharma Inc.
  • RedHill Biopharma Ltd.
  • SK Biopharmaceuticals Co., Ltd.
  • 大日本住友製藥
  • Synergy Pharmaceuticals, Inc.
  • Synthetic Biologics, Inc.
  • 武田藥品工業

激躁性結腸症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

激躁性結腸症:最近的開發平台趨勢

激躁性結腸症:暫停中的計劃

激躁性結腸症:開發中止的產品

激躁性結腸症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8649IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2016, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10, 6, 9 and 1 respectively.Irritable Bowel Syndrome.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Irritable Bowel Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Irritable Bowel Syndrome - Overview
  • Irritable Bowel Syndrome - Therapeutics under Development by Companies
  • Irritable Bowel Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Irritable Bowel Syndrome - Products under Development by Companies
  • Irritable Bowel Syndrome - Companies Involved in Therapeutics Development
    • 4D Pharma Plc
    • A. Menarini Industrie Farmaceutiche Riunite Srl
    • Alfa Wassermann S.p.A
    • Ardelyx, Inc.
    • Astellas Pharma Inc.
    • CJ HealthCare Corp.
    • Dong-A Socio Holdings Co. Ltd.
    • Enterome Bioscience SA
    • GlaxoSmithKline Plc
    • Innovative Med Concepts, LLC
    • Ironwood Pharmaceuticals, Inc.
    • Kissei Pharmaceutical Co., Ltd.
    • Lexicon Pharmaceuticals, Inc.
    • Napo Pharmaceuticals Inc
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • RaQualia Pharma Inc.
    • RedHill Biopharma Ltd.
    • SK Biopharmaceuticals Co., Ltd.
    • Sumitomo Dainippon Pharma Co Ltd
    • Synergy Pharmaceuticals, Inc.
    • Synthetic Biologics, Inc.
    • Vitality Biopharma Inc
  • Irritable Bowel Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (celecoxib + famciclovir) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-1017 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-7147 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bedoradrine sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Blautix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CJ-14199 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crofelemer DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSTI-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DA-6886 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-6952 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EB-420 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3179106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibodutant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • linaclotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lovastatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-4006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LX-1033 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-2952 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBF-677 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plecanatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relenopride hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rifaximin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00202730 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00310941 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solabegron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tenapanor hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Irritable Bowel Syndrome - Dormant Projects
  • Irritable Bowel Syndrome - Discontinued Products
  • Irritable Bowel Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results
      • Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting
      • Oct 17, 2016: Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology Annual Scientific Meeting
      • Sep 28, 2016: Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at Upcoming Scientific Meeting and Provides Update on IBS-C Program
      • Aug 02, 2016: Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation
      • Jul 19, 2016: 4D Pharma Provides Phase I Clinical Trial Update
      • Jul 15, 2016: Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program
      • Jun 20, 2016: RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA for IBS-D
      • May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin
      • May 23, 2016: Phase I trial Update On Blautix For The Treatment Of Irritable Bowel Syndrome : 4D pharma
      • May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
      • May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016
      • May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
      • May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016
      • May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Irritable Bowel Syndrome, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H2 2016
  • Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016
  • Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H2 2016
  • Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H2 2016
  • Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H2 2016
  • Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp., H2 2016
  • Irritable Bowel Syndrome - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
  • Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H2 2016
  • Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Irritable Bowel Syndrome - Pipeline by Innovative Med Concepts, LLC, H2 2016
  • Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
  • Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
  • Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H2 2016
  • Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Irritable Bowel Syndrome - Pipeline by Pfizer Inc., H2 2016
  • Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H2 2016
  • Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016
  • Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H2 2016
  • Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Irritable Bowel Syndrome - Dormant Projects, H2 2016
  • Irritable Bowel Syndrome - Dormant Projects (Contd..1), H2 2016
  • Irritable Bowel Syndrome - Dormant Projects (Contd..2), H2 2016
  • Irritable Bowel Syndrome - Dormant Projects (Contd..3), H2 2016
  • Irritable Bowel Syndrome - Dormant Projects (Contd..4), H2 2016
  • Irritable Bowel Syndrome - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Irritable Bowel Syndrome, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top